136 related articles for article (PubMed ID: 38419274)
1. Comparison between tofacitinib and ustekinumab as a third-line therapy in refractory ulcerative colitis: A multicenter international study.
Allocca M; Catalano G; Savarino EV; Chaparro M; Levartovsky A; Michalopoulos G; Viazis N; Fousekis FS; Psistakis A; Noviello D; Nascimento CND; Caron B; Kitsou V; Bamias G; García MJ; Zacharopoulou E; Foteinogiannopoulou K; D'Amico F; Koutroubakis I; Ellul P; Tzouvala M; Peyrin-Biroulet L; Torres J; Caprioli F; Karmiris K; Theodoropoulou A; Katsanos KH; Christodoulou DK; Mantzaris GJ; Kopylov U; Gisbert JP; Danese S; Magro F; Carla F; Fiorino G
United European Gastroenterol J; 2024 Jun; 12(5):543-551. PubMed ID: 38419274
[TBL] [Abstract][Full Text] [Related]
2. Tofacitinib for ulcerative colitis: results of the prospective Dutch Initiative on Crohn and Colitis (ICC) registry.
Biemans VBC; Sleutjes JAM; de Vries AC; Bodelier AGL; Dijkstra G; Oldenburg B; Löwenberg M; van Bodegraven AA; van der Meulen-de Jong AE; de Boer NKH; Srivastava N; West RL; Römkens TEH; Horjus Talabur Horje CS; Jansen JM; van der Woude CJ; Hoekstra J; Weersma RK; van Schaik FDM; Hoentjen F; Pierik MJ;
Aliment Pharmacol Ther; 2020 May; 51(9):880-888. PubMed ID: 32237087
[TBL] [Abstract][Full Text] [Related]
3. Oral Janus kinase inhibitors for maintenance of remission in ulcerative colitis.
Davies SC; Hussein IM; Nguyen TM; Parker CE; Khanna R; Jairath V
Cochrane Database Syst Rev; 2020 Jan; 1(1):CD012381. PubMed ID: 31984480
[TBL] [Abstract][Full Text] [Related]
4. 1-Year Comparative Effectiveness of Tofacitinib vs Ustekinumab for Patients With Ulcerative Colitis and Prior Antitumor Necrosis Factor Failure.
Dalal RS; Sharma PP; Bains K; Pruce JC; Allegretti JR
Inflamm Bowel Dis; 2024 Mar; 30(3):395-401. PubMed ID: 37209416
[TBL] [Abstract][Full Text] [Related]
5. Real-World Experience with Tofacitinib in IBD at a Tertiary Center.
Weisshof R; Aharoni Golan M; Sossenheimer PH; El Jurdi K; Ollech JE; Pekow J; Cohen RD; Sakuraba A; Dalal S; Rubin DT
Dig Dis Sci; 2019 Jul; 64(7):1945-1951. PubMed ID: 30734234
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of biologic agents and tofacitinib in moderate-to-severe ulcerative colitis: A systematic overview of meta-analyses.
Pantavou K; Yiallourou AI; Piovani D; Evripidou D; Danese S; Peyrin-Biroulet L; Bonovas S; Nikolopoulos GK
United European Gastroenterol J; 2019 Dec; 7(10):1285-1303. PubMed ID: 31839954
[TBL] [Abstract][Full Text] [Related]
7. Real-world evidence of tofacitinib effectiveness and safety in patients with refractory ulcerative colitis.
Lair-Mehiri L; Stefanescu C; Vaysse T; Laharie D; Roblin X; Rosa I; Treton X; Abitbol V; Amiot A; Bouguen G; Dib N; Fumery M; Pariente B; Carbonnel F; Peyrin-Biroulet L; Simon M; Viennot S; Bouhnik Y
Dig Liver Dis; 2020 Mar; 52(3):268-273. PubMed ID: 31732444
[TBL] [Abstract][Full Text] [Related]
8. Effect of Tofacitinib on One-Year Colectomy Risk in Anti-TNF Refractory Ulcerative Colitis: A Prospective Multicenter Italian Study.
Carvalhas Gabrielli AM; Ferretti F; Monico CM; Tombetti E; Maconi G; Romeo S; Piazza O Sed N; Caprioli F; Mazzola AM; Alicante S; Bertè R; Lolli E; Scribano ML; Buscarini E; Ricci C; Carmagnola S; Ardizzone S; Cannatelli R
Dig Dis Sci; 2024 May; 69(5):1785-1792. PubMed ID: 38530500
[TBL] [Abstract][Full Text] [Related]
9. Biologics or tofacitinib for people with rheumatoid arthritis unsuccessfully treated with biologics: a systematic review and network meta-analysis.
Singh JA; Hossain A; Tanjong Ghogomu E; Mudano AS; Maxwell LJ; Buchbinder R; Lopez-Olivo MA; Suarez-Almazor ME; Tugwell P; Wells GA
Cochrane Database Syst Rev; 2017 Mar; 3(3):CD012591. PubMed ID: 28282491
[TBL] [Abstract][Full Text] [Related]
10. Matching-Adjusted Indirect Comparisons of Filgotinib vs Vedolizumab, Tofacitinib, and Ustekinumab for Moderately to Severely Active Ulcerative Colitis.
Lu X; Zhou ZY; Xin Y; Wang MJ; Gray E; Jairath V; Lindsay JO
Inflamm Bowel Dis; 2024 Jan; 30(1):64-77. PubMed ID: 36946138
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of tofacitinib dose de-escalation and dose escalation for patients with ulcerative colitis: results from OCTAVE Open.
Sands BE; Armuzzi A; Marshall JK; Lindsay JO; Sandborn WJ; Danese S; Panés J; Bressler B; Colombel JF; Lawendy N; Maller E; Zhang H; Chan G; Salese L; Tsilkos K; Marren A; Su C
Aliment Pharmacol Ther; 2020 Jan; 51(2):271-280. PubMed ID: 31660640
[TBL] [Abstract][Full Text] [Related]
12. Dual Biologic and Small Molecule Therapy for the Treatment of Refractory Pediatric Inflammatory Bowel Disease.
Dolinger MT; Spencer EA; Lai J; Dunkin D; Dubinsky MC
Inflamm Bowel Dis; 2021 Jul; 27(8):1210-1214. PubMed ID: 33125058
[TBL] [Abstract][Full Text] [Related]
13. Comparative effectiveness of second-line biological therapies for ulcerative colitis and Crohn's disease in patients with prior failure of anti-tumour necrosis factor treatment.
Hyun HK; Zhang HS; Yu J; Kang EA; Park J; Park SJ; Park JJ; Kim TI; Kim WH; Cheon JH
BMC Gastroenterol; 2022 Mar; 22(1):143. PubMed ID: 35346063
[TBL] [Abstract][Full Text] [Related]
14. Exposure-response characterization of tofacitinib efficacy in moderate to severe ulcerative colitis: Results from a dose-ranging phase 2 trial.
Mukherjee A; Hazra A; Smith MK; Martin SW; Mould DR; Su C; Niezychowski W
Br J Clin Pharmacol; 2018 Jun; 84(6):1136-1145. PubMed ID: 29377257
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness of tofacitinib compared with infliximab, adalimumab, golimumab, vedolizumab and ustekinumab for the treatment of moderate to severe ulcerative colitis in Germany.
Sardesai A; Dignass A; Quon P; Milev S; Cappelleri JC; Kisser A; Modesto I; Sharma PP
J Med Econ; 2021; 24(1):279-290. PubMed ID: 33502905
[TBL] [Abstract][Full Text] [Related]
16. First- and Second-Line Pharmacotherapies for Patients With Moderate to Severely Active Ulcerative Colitis: An Updated Network Meta-Analysis.
Singh S; Murad MH; Fumery M; Dulai PS; Sandborn WJ
Clin Gastroenterol Hepatol; 2020 Sep; 18(10):2179-2191.e6. PubMed ID: 31945470
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of biologic and small molecule agents as second-line therapy after exposure to TNF inhibitors in patients with ulcerative colitis: A propensity-matched cohort study.
Kochhar GS; Desai A; Farraye FA; Cross RK; El-Hachem S; Dulai PS; Regueiro M
Aliment Pharmacol Ther; 2023 Aug; 58(3):297-308. PubMed ID: 37300328
[TBL] [Abstract][Full Text] [Related]
18. Real-world Effectiveness of Tofacitinib for Moderate to Severe Ulcerative Colitis: A Multicentre UK Experience.
Honap S; Chee D; Chapman TP; Patel M; Kent AJ; Ray S; Sharma E; Kennedy J; Cripps S; Walsh A; Goodhand JR; Ahmad T; Satsangi J; Irving PM; Kennedy NA;
J Crohns Colitis; 2020 Oct; 14(10):1385-1393. PubMed ID: 32280965
[TBL] [Abstract][Full Text] [Related]
19. Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis.
Sandborn WJ; Su C; Sands BE; D'Haens GR; Vermeire S; Schreiber S; Danese S; Feagan BG; Reinisch W; Niezychowski W; Friedman G; Lawendy N; Yu D; Woodworth D; Mukherjee A; Zhang H; Healey P; Panés J;
N Engl J Med; 2017 May; 376(18):1723-1736. PubMed ID: 28467869
[TBL] [Abstract][Full Text] [Related]
20. Clinical outcomes with ustekinumab as rescue treatment in therapy-refractory or therapy-intolerant ulcerative colitis.
Ochsenkühn T; Tillack C; Szokodi D; Janelidze S; Schnitzler F
United European Gastroenterol J; 2020 Feb; 8(1):91-98. PubMed ID: 32213052
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
